- Home
- AG vs MYGN Comparison
AG vs MYGN Comparison
Compare AG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- MYGN
- Stock Information
- Founded
- AG 1979
- MYGN 1991
- Country
- AG Canada
- MYGN United States
- Employees
- AG N/A
- MYGN N/A
- Industry
- AG Precious Metals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AG Basic Materials
- MYGN Health Care
- Exchange
- AG Nasdaq
- MYGN Nasdaq
- Market Cap
- AG 4.1B
- MYGN 744.7M
- IPO Year
- AG N/A
- MYGN 1995
- Fundamental
- Price
- AG $8.51
- MYGN $5.63
- Analyst Decision
- AG Buy
- MYGN Hold
- Analyst Count
- AG 2
- MYGN 15
- Target Price
- AG $8.75
- MYGN $15.14
- AVG Volume (30 Days)
- AG 28.3M
- MYGN 1.7M
- Earning Date
- AG 07-31-2025
- MYGN 08-05-2025
- Dividend Yield
- AG 0.23%
- MYGN N/A
- EPS Growth
- AG N/A
- MYGN N/A
- EPS
- AG N/A
- MYGN N/A
- Revenue
- AG $698,532,000.00
- MYGN $831,300,000.00
- Revenue This Year
- AG $68.65
- MYGN N/A
- Revenue Next Year
- AG $9.36
- MYGN $6.68
- P/E Ratio
- AG N/A
- MYGN N/A
- Revenue Growth
- AG 33.60
- MYGN 7.38
- 52 Week Low
- AG $4.43
- MYGN $3.81
- 52 Week High
- AG $8.70
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- AG 65.60
- MYGN 60.69
- Support Level
- AG $7.93
- MYGN $4.90
- Resistance Level
- AG $8.57
- MYGN $5.74
- Average True Range (ATR)
- AG 0.32
- MYGN 0.27
- MACD
- AG -0.05
- MYGN 0.11
- Stochastic Oscillator
- AG 78.16
- MYGN 88.78
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.